SSY Group (HKG:2005) said 32 of its products, comprising 37 specifications, were newly included in the 2026 edition of China's National Essential Medicines List.
This brings the total number of the group's products on the list to 95, covering 141 specifications, according to a Friday Hong Kong bourse filing. The updated list will take effect on Sept. 1.
The pharmaceutical company said the inclusion is expected to support its business growth and development.
Shares of the pharmaceutical company rose 2% in recent trade.